<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Only local ablation (radiofrequency ablation, cryotherapy) or esophagectomy currently is available to treat high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Alternative treatments, specifically chemopreventive strategies, are lacking </plain></SENT>
<SENT sid="2" pm="."><plain>Our understanding of the molecular changes of high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> offers an opportunity to inhibit <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> of high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Increased activity of the Src kinase and deregulation of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor p27 are features of malignant cells and high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Src phosphorylates p27, inhibiting its regulatory function and increasing cell growth and proliferation </plain></SENT>
<SENT sid="5" pm="."><plain>We hypothesized that a small molecule inhibitor of Src might reduce the growth and reverse Src-mediated deregulation of p27 in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> cells </plain></SENT>
<SENT sid="6" pm="."><plain>METHODS: Immortalized <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> cell lines established from patient biopsies were treated with the Src kinase inhibitor <z:chebi fb="0" ids="49375">dasatinib</z:chebi> and evaluated for p27 localization and protein levels, as well as for effects on the cell cycle and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> using flow cytometry, viability assays, and protein and <z:chebi fb="40" ids="33697">RNA</z:chebi> markers </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: <z:chebi fb="0" ids="49375">Dasatinib</z:chebi> reduced both Src activation and p27 phosphorylation and increased p27 protein levels and nuclear localization </plain></SENT>
<SENT sid="8" pm="."><plain>These effects correlated with decreased proliferation, cell-cycle arrest, and activation of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain>Analysis of biopsies of patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> revealed the presence of phosphorylated p27 in high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, consistent with in vitro findings </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="49375">Dasatinib</z:chebi> has considerable <z:chebi fb="0" ids="35610">antineoplastic</z:chebi> effects on <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> cell lines carrying genetic markers associated with <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, which correlates with the reversal of p27 deregulation </plain></SENT>
<SENT sid="11" pm="."><plain>These findings suggest that <z:chebi fb="0" ids="49375">dasatinib</z:chebi> has potential as a treatment for patients with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and that p27 holds promise as a biomarker in the clinical use of <z:chebi fb="0" ids="49375">dasatinib</z:chebi> in patients with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
</text></document>